Cargando…
Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study
OBJECTIVE: The aim of this study was to investigate the impact of adverse events (AEs) on health utility and health-related quality of life (HRQOL) in patients with metastatic breast cancer undergoing first-line chemotherapy. METHODS: We analyzed the data from the SELECT BC study, a multicenter, ope...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805818/ https://www.ncbi.nlm.nih.gov/pubmed/29043567 http://dx.doi.org/10.1007/s40273-017-0580-7 |
_version_ | 1783299034980548608 |
---|---|
author | Hagiwara, Yasuhiro Shiroiwa, Takeru Shimozuma, Kojiro Kawahara, Takuya Uemura, Yukari Watanabe, Takanori Taira, Naruto Fukuda, Takashi Ohashi, Yasuo Mukai, Hirofumi |
author_facet | Hagiwara, Yasuhiro Shiroiwa, Takeru Shimozuma, Kojiro Kawahara, Takuya Uemura, Yukari Watanabe, Takanori Taira, Naruto Fukuda, Takashi Ohashi, Yasuo Mukai, Hirofumi |
author_sort | Hagiwara, Yasuhiro |
collection | PubMed |
description | OBJECTIVE: The aim of this study was to investigate the impact of adverse events (AEs) on health utility and health-related quality of life (HRQOL) in patients with metastatic breast cancer undergoing first-line chemotherapy. METHODS: We analyzed the data from the SELECT BC study, a multicenter, open-label, randomized, phase III study conducted in Japan, which compared first-line S-1 with taxane therapies. Heath utility and HRQOL were assessed using the EQ-5D-3L and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) at baseline and 3, 6, and 12 months after treatment initiation. Health utility was calculated based on societal preferences, and AEs were reported at each cycle of the study treatment. Linear marginal mean models were used to quantify the impact of the last AEs (with 10 or more incidences) observed before HRQOL assessment on health utility and HRQOL. RESULTS: Analysis included 380 patients and 12 (of 15) AEs. Grade 1 nausea and oral mucositis, grade 1 and 2 edema, and grade 2 fatigue, motor and sensory neuropathy, and myalgia were significantly associated with disutility, measured using the EQ-5D-3L. Grade 1 oral mucositis, grade 1 and 2 fatigue, and grade 2 sensory neuropathy were significantly associated with impaired global health status in the EORTC QLQ-C30. AEs associated with decrements in the five functioning scales included fatigue, oral mucositis, nausea, edema, motor and sensory neuropathy, and myalgia. CONCLUSIONS: We reported disutilities caused by AEs in patients with metastatic breast cancer under chemotherapy. These findings can be applied to future model-based cost-effectiveness analyses. TRIAL REGISTRATION NUMBER: C000000416. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40273-017-0580-7) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5805818 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-58058182018-02-14 Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study Hagiwara, Yasuhiro Shiroiwa, Takeru Shimozuma, Kojiro Kawahara, Takuya Uemura, Yukari Watanabe, Takanori Taira, Naruto Fukuda, Takashi Ohashi, Yasuo Mukai, Hirofumi Pharmacoeconomics Original Research Article OBJECTIVE: The aim of this study was to investigate the impact of adverse events (AEs) on health utility and health-related quality of life (HRQOL) in patients with metastatic breast cancer undergoing first-line chemotherapy. METHODS: We analyzed the data from the SELECT BC study, a multicenter, open-label, randomized, phase III study conducted in Japan, which compared first-line S-1 with taxane therapies. Heath utility and HRQOL were assessed using the EQ-5D-3L and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) at baseline and 3, 6, and 12 months after treatment initiation. Health utility was calculated based on societal preferences, and AEs were reported at each cycle of the study treatment. Linear marginal mean models were used to quantify the impact of the last AEs (with 10 or more incidences) observed before HRQOL assessment on health utility and HRQOL. RESULTS: Analysis included 380 patients and 12 (of 15) AEs. Grade 1 nausea and oral mucositis, grade 1 and 2 edema, and grade 2 fatigue, motor and sensory neuropathy, and myalgia were significantly associated with disutility, measured using the EQ-5D-3L. Grade 1 oral mucositis, grade 1 and 2 fatigue, and grade 2 sensory neuropathy were significantly associated with impaired global health status in the EORTC QLQ-C30. AEs associated with decrements in the five functioning scales included fatigue, oral mucositis, nausea, edema, motor and sensory neuropathy, and myalgia. CONCLUSIONS: We reported disutilities caused by AEs in patients with metastatic breast cancer under chemotherapy. These findings can be applied to future model-based cost-effectiveness analyses. TRIAL REGISTRATION NUMBER: C000000416. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40273-017-0580-7) contains supplementary material, which is available to authorized users. Springer International Publishing 2017-10-17 2018 /pmc/articles/PMC5805818/ /pubmed/29043567 http://dx.doi.org/10.1007/s40273-017-0580-7 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Article Hagiwara, Yasuhiro Shiroiwa, Takeru Shimozuma, Kojiro Kawahara, Takuya Uemura, Yukari Watanabe, Takanori Taira, Naruto Fukuda, Takashi Ohashi, Yasuo Mukai, Hirofumi Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study |
title | Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study |
title_full | Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study |
title_fullStr | Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study |
title_full_unstemmed | Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study |
title_short | Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study |
title_sort | impact of adverse events on health utility and health-related quality of life in patients receiving first-line chemotherapy for metastatic breast cancer: results from the select bc study |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805818/ https://www.ncbi.nlm.nih.gov/pubmed/29043567 http://dx.doi.org/10.1007/s40273-017-0580-7 |
work_keys_str_mv | AT hagiwarayasuhiro impactofadverseeventsonhealthutilityandhealthrelatedqualityoflifeinpatientsreceivingfirstlinechemotherapyformetastaticbreastcancerresultsfromtheselectbcstudy AT shiroiwatakeru impactofadverseeventsonhealthutilityandhealthrelatedqualityoflifeinpatientsreceivingfirstlinechemotherapyformetastaticbreastcancerresultsfromtheselectbcstudy AT shimozumakojiro impactofadverseeventsonhealthutilityandhealthrelatedqualityoflifeinpatientsreceivingfirstlinechemotherapyformetastaticbreastcancerresultsfromtheselectbcstudy AT kawaharatakuya impactofadverseeventsonhealthutilityandhealthrelatedqualityoflifeinpatientsreceivingfirstlinechemotherapyformetastaticbreastcancerresultsfromtheselectbcstudy AT uemurayukari impactofadverseeventsonhealthutilityandhealthrelatedqualityoflifeinpatientsreceivingfirstlinechemotherapyformetastaticbreastcancerresultsfromtheselectbcstudy AT watanabetakanori impactofadverseeventsonhealthutilityandhealthrelatedqualityoflifeinpatientsreceivingfirstlinechemotherapyformetastaticbreastcancerresultsfromtheselectbcstudy AT tairanaruto impactofadverseeventsonhealthutilityandhealthrelatedqualityoflifeinpatientsreceivingfirstlinechemotherapyformetastaticbreastcancerresultsfromtheselectbcstudy AT fukudatakashi impactofadverseeventsonhealthutilityandhealthrelatedqualityoflifeinpatientsreceivingfirstlinechemotherapyformetastaticbreastcancerresultsfromtheselectbcstudy AT ohashiyasuo impactofadverseeventsonhealthutilityandhealthrelatedqualityoflifeinpatientsreceivingfirstlinechemotherapyformetastaticbreastcancerresultsfromtheselectbcstudy AT mukaihirofumi impactofadverseeventsonhealthutilityandhealthrelatedqualityoflifeinpatientsreceivingfirstlinechemotherapyformetastaticbreastcancerresultsfromtheselectbcstudy |